| Autor: |
Pue, M. A., Pratt, S. K., Fairless, A. J., Fowles, S., Laroche, J., Georgiou, P., Prince, W. |
| Předmět: |
|
| Zdroj: |
Journal of Antimicrobial Chemotherapy (JAC); Jan1994, Vol. 33 Issue 1, p119-127, 9p |
| Abstrakt: |
Twenty healthy male volunteers received single oral doses of famciclovir (125–750 mg), in a randomized, single-blind, crossover study. Plasma and urine concentrations of penciclovir and its 6-deoxy precursor, BRL 42359, were determined and penciclovir plasma concentration-time data submitted to model-independent pharmacokinetic analysis. Peak plasma concentrations of penciclovir were obtained at median times of 0.5–0.75 h after dosing. The areas under the concentration versus time curves (AUC) and the peak penciclovir concentration (C) increased linearly with dose of famciclovir. Time to C, elimination half-life, urinary recovery and renal clearance of penciclovir did not change with increasing dose. Famciclovir was excreted via the kidneys as penciclovir (60%) and BRL 42359 (5%), respectively. Famciclovir was well tolerated by all subjects with a low incidence of adverse effects. In conclusion, penciclovir thus displays linear pharmacokinetics in the anticipated therapeutic dose range of famciclovir. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
